17,365 Shares in Inari Medical, Inc. (NASDAQ:NARI) Bought by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in shares of Inari Medical, Inc. (NASDAQ:NARI) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 17,365 shares of the company’s stock, valued at approximately $716,000.

Other hedge funds have also bought and sold shares of the company. GAMMA Investing LLC raised its stake in Inari Medical by 164.7% during the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after buying an additional 438 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares during the last quarter. KBC Group NV raised its stake in Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after buying an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after buying an additional 522 shares during the last quarter. Finally, Covestor Ltd raised its stake in Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after buying an additional 926 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

Inari Medical Price Performance

Shares of NASDAQ NARI opened at $51.92 on Friday. The stock has a market capitalization of $3.04 billion, a P/E ratio of -38.46 and a beta of 0.96. The company has a 50-day moving average price of $46.14 and a 200-day moving average price of $47.48. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $67.13.

Insider Activity

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. This represents a 0.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the completion of the sale, the director now owns 601,233 shares of the company’s stock, valued at approximately $27,067,509.66. This trade represents a 6.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 186,000 shares of company stock worth $8,990,990 over the last three months. 10.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NARI. Deutsche Bank Aktiengesellschaft started coverage on shares of Inari Medical in a research note on Friday, August 9th. They set a “buy” rating and a $68.00 target price for the company. Leerink Partners started coverage on shares of Inari Medical in a report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price target for the company. Canaccord Genuity Group raised their price target on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Robert W. Baird raised their price target on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a report on Tuesday, October 29th. Finally, Truist Financial raised their price target on shares of Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a report on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $58.89.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.